Anders Mellemgaard

11.6k citations
144 papers · 7.6k indexed · 3 hit papers · h-index 41

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Renal cell carcinoma treatment

Papers in

    • Lung Cancer Research Studies 31
    • Colorectal Cancer Treatments and Studies 12
    • Colorectal Cancer Screening and Detection 12
    • Global Cancer Incidence and Screening 10
    • Lung Cancer Treatments and Mutations 60
    • Lung Cancer Diagnosis and Treatment 27
    • Renal cell carcinoma treatment 11

Anders Mellemgaard

143 papers receiving 7.4k citations

Hit Papers

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study 2020 · 295 citations
295200820262014202050010001.5k2.0k

Peers

Anders Mellemgaard
Comparison fields: 5 of 139
  • Oncology 4.1k
  • Pulmonary and Respiratory Medicine 4.6k
  • Cancer Research 1.1k
  • Pathology and Forensic Medicine 587
  • Hepatology 238
Replace Bruce G. Redman with:
Bruce G. Redman United States
Rossana Berardi Italy
Boštjan Šeruga Canada
Jee Hyun Kim South Korea
Arnoud J. Templeton Switzerland
Katsuyuki Hotta Japan
Olivier Rixe France
Sinéad Cuffe Ireland
Philip Bonomi United States
K. Mattson Finland
Anders Mellemgaard relative to Bruce G. Redman United States Bruce G. Redman's profile →
Citations per field
00.5×1.7×
Bruce G. Redman · 1×
Citations per year

Countries citing papers authored by Anders Mellemgaard

Since Specialization
Citations

This map shows the geographic impact of Anders Mellemgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Mellemgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Mellemgaard more than expected).

Fields of papers citing papers by Anders Mellemgaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Mellemgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Mellemgaard. The network helps show where Anders Mellemgaard may publish in the future.

Co-authors

The 25 scholars most cited alongside Anders Mellemgaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anders Mellemgaard Line = papers co-authored together Anders Mellemgaard links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Hit paper breakdown →
20082487
2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Hit paper breakdown →
2014694
3 1994349
4
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Hit paper breakdown →
2020295
5 1990209
6 1995157
7 1996137
8 1995137
9 1995135
10 2020123
11 1995107
12 2013100
13 2016100
14 199593
15 199473
16 201271
17 199669
18 199467
19 201364
20 199563

About Anders Mellemgaard

Anders Mellemgaard is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Biological Psychiatry, Epidemiology and Pathology and Forensic Medicine, having authored 144 papers that have together received 7.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (60 papers), Lung Cancer Research Studies (31 papers), Lung Cancer Diagnosis and Treatment (27 papers), Multiple and Secondary Primary Cancers (18 papers), Colorectal Cancer Treatments and Studies (12 papers), Colorectal Cancer Screening and Detection (12 papers), Renal cell carcinoma treatment (11 papers) and Global Cancer Incidence and Screening (10 papers). The work is most often cited by research in Oncology (4.1k citations), Pulmonary and Respiratory Medicine (4.6k citations), Cancer Research (1.1k citations), Pathology and Forensic Medicine (587 citations) and Hepatology (238 citations). Anders Mellemgaard has collaborated with scholars based in Denmark, United States and United Kingdom. Frequent co-authors include Jørgen H. Olsen, Joachim von Pawel, Henrik Møller, Giorgio V. Scagliotti, Piotr Serwatowski, Christian Manegold, Tuncay Göksel, Keunchil Park, Johan Vansteenkiste and Filippo de Marinis. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Cancer, European Journal of Cancer, Annals of Oncology and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026